Manuela Valente Sells 2,597 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• Manuela Valente sold 2,597 SOPH shares on April 6 at an average price of $4.85 for $12,595.45 under a pre-arranged Rule 10b5-1 plan to cover tax withholding, leaving her with 221,651 shares (a 1.16% reduction).
• SOPH recently traded around $4.89 with a market cap of $334.64M; the company reported an EPS miss (‑$0.28 vs. ‑$0.20 est.) on $21.71M revenue (slightly above estimates) and continues to show negative margins and ROE.
• Institutional activity includes UBS Asset Management boosting its stake to 7.63M shares, institutional owners hold 31.59% of the stock, and analyst sentiment is mixed with a consensus target of $7 (two Buys, one Sell resulting in a Hold average).

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Manuela Valente sold 2,597 shares of SOPHiA GENETICS stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $4.85, for a total transaction of $12,595.45. Following the sale, the insider directly owned 221,651 shares in the company, valued at $1,075,007.35. The trade was a 1.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Tuesday, April 7th, Manuela Valente sold 2,376 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total transaction of $11,571.12.
• On Thursday, March 19th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $1,820.20.

SOPHiA GENETICS Trading Down 0.3%

Shares of SOPH traded down $0.01 during trading hours on Wednesday, reaching $4.89. 64,929 shares of the company traded hands, compared to its average volume of 188,371. The company's fifty day moving average price is $4.78 and its two-hundred day moving average price is $4.68. The company has a market capitalization of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. Equities research analysts predict that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC boosted its stake in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Alta Wealth Advisors LLC bought a new stake in SOPHiA GENETICS during the third quarter worth about $6,708,000. Royce & Associates LP bought a new stake in SOPHiA GENETICS during the fourth quarter worth about $2,009,000. Finally, 1492 Capital Management LLC bought a new stake in SOPHiA GENETICS during the fourth quarter worth about $973,000. Institutional investors own 31.59% of the company's stock.

Wall Street Analysts Forecast Growth

SOPH has been the topic of a number of research reports. BTIG Research reaffirmed a "buy" rating and set a $7.00 target price on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Guggenheim lifted their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, SOPHiA GENETICS presently has an average rating of "Hold" and a consensus target price of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.